Service médecine foetale-Hôpital Trousseau
Paris, 75012, France
NCT Number: NCT04770805
The purpose of the study is to evaluate the feasibility and the maternal, fetal and postnatal outcomes of sacral myelomeningocele (MMC) and Myelic Limited Dorsal Myeloschisis (MyeLDM) fetoscopic repair at Trousseau Hospital (Paris, France).
This study is active but is not currently recruiting participants.
Notify Me18 year and older
Female
Interventional
Not applicable
Paris, 75012, France
Myelomeningocele and Myelic limited dorsal myeloschisis (MyeLDM) correspond to neural tube defects which lead to lifelong disabilities including lower extremity paralysis, sphincters deficiency, and cerebral complications (Chiari 2 malformation and hydrocephalus). It is demonstrated that fetal surgery repair of MMC with upper limit between the first thoracic vertebra (T1) and the first sacral vertebra (S1) improves motor and cerebral prognosis. Nowadays, this fetal surgery is performed either after maternal laparotomy and hysterotomy (open fetal surgery) or using fetoscopy. the investigators, at Trousseau Hospital (APHP, Paris), initiated an open fetal surgery of MMC program called PRIUM1 and 16 fetuses has been currently operated.
Fetoscopic repair of MMC is proposed by several international groups in order to prevent from maternal and obstetric morbidity related to the hysterotomy and improve the mother's obstetrical prognosis by allowing vaginal delivery. Results of fetoscopic MMC repair are very satisfying, both in terms of repair surgery efficacy and in terms of obstetrical prognosis. The research team believe that it is justified to propose this minimally invasive repair technique using fetoscopy, for represented by sacral MMC (level S1 and lower) as well as for intermediate forms between open and closed dysgraphisms, represented by MyeLDM. Indeed, these dysraphism are associated with the same cerebral complications than MMC with upper limit between T1 and S1 which could be corrected with prenatal repair. In addition, the spinal cord protection offered by prenatal surgery could prevent from the neuroepithelium destruction observed during pregnancy, with a potential motor benefit for the children.
The main objective of PRIUM 2 is to evaluate the success of fetoscopic surgical repair of sacral MMC or MyeLDM with a birth after 32 weeks of gestation and without severe perinatal morbidity and mortality.
The secondary objectives of PRIUM 2 are to evaluate the complications of pregnancy related to fetoscopic surgery as well as to evaluate the prenatal and postnatal evolution of the cerebral complications (Chiari 2 malformation and hydrocephalus) after fetoscopic repair surgery of the dysraphism (up to 12 months of age).
In this protocol, fetal sacral MMC/ MyeLDM repair surgery will be performed using gas fetoscopy before 26 weeks. After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will be performed by a multidisciplinary team (maternal fetal medicine specialists, pediatric neurosurgeons, pediatric surgeons).
After discharge, patients will be followed weekly by a midwife and every two weeks by a referring obstetrician who will perform a clinical examination and a fetal ultrasound.A post procedure MRI will be performed 4 weeks after the surgery. If there is no obstetrical contraindication, vaginal delivery will be authorized.
The children will be followed according to the conventional management of children with dysraphisms and consultations at 8 weeks of life and 12 months of life will be scheduled at Trousseau Hospital, with the multidisciplinary team (pediatric neurosurgeons, physical medicine and rehabilitation specialists, pediatric orthopedic surgeons). During these two consultations, the children will have a complete clinical examination, a cerebral and spinal MRI and an ultrasound of the urinary tract.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
Exclusion criteria
After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
Time frame: From time of surgery to 8 weeks of life (up to 28 weeks)
Successful complete closure of the defect using the fetoscopic technique AND birth after 32 weeks without severe perinatal morbidity and mortality including grade III-IV intra ventricular hemorrhage, severe, cerebral parenchyma hemorrhage, periventricular leukomalacia, grade III ulcero-necrotizing enterocolitis, severe bronchodysplasia)
Time frame: during the surgery
diagnosis of maternal gas embolism, hemorrhage, thromboembolic complication, death
Time frame: From time of surgery until 37 weeks of gestation
Preterm labor occuring at any time from surgery leading to delivery before 37 weeks of gestation
Time frame: From time of surgery until 37 weeks of gestation
Preterm premature rupture of membranes occuring at any time from surgery until 37 weeks of gestation
Time frame: From time of surgery until 37 weeks of gestation
chorioamnionitis occuring at any time from surgery until 37 weeks of gestation
Time frame: From time of surgery until 34 weeks of gestation
indication for a betamethasone course occuring at any time from surgery until 34 weeks of gestation
Time frame: From time of surgery until 37 weeks of gestation
hypertensive disorders, preeclampsia, gestational diabetes occuring any time from surgery until 37 weeks of gestation
Time frame: From time of surgery until birth
Difference in the growth of the cephalic perimeter measured on an axial ultrasound section
Time frame: From time of surgery until birth
Difference in measurement of the ventricles on an axial ultrasound section
Time frame: From time of surgery until birth
Difference in the measurement of the large retro-cerebellar cistern on an axial section of the posterior fossa
Time frame: From time of surgery until birth
Proportion of patients with reversal of hindbrain herniation (i.e. lower limit of the vermis located above the foramen magnum on ultrasound and/or fetal MRI)
Time frame: From time of surgery until delivery
Gestational age of delivery regardless of indication
Time frame: From time of surgery until delivery
Proportion of deliveries before 37 weeks of gestation
Time frame: From time of surgery until delivery
Mode of delivery - either vaginal or cesarean section
Time frame: From time of surgery until delivery
Maternal obstetric outcome as evidenced by postpartum hemorrhage Proportion of postpartum hemorrhages defined by blood loss of more than 500mL for vaginal delivery, and 800mL for cesarean delivery
Time frame: From time of surgery until delivery
Maternal obstetric outcome as evidenced by postpartum hemorrhage Need for maternal transfusion (number of blood cells transfused)
Time frame: at birth
Normal or abnormal birth parameters at birth depending on the term
Time frame: at birth
Proportion of fetal asphyxia (arterial pH at the umbilical cord <7.00)
Time frame: From the time of birth until 8 weeks of life
need for one of the following neurosurgery
Time frame: From the time of birth until 12 months of life
Difference in the growth of the cephalic perimeter by measuring the cranial perimeter between birth and the age of 12 months
Time frame: From the time of birth until 12 months of life
Difference in the measurement of the cerebral lateral ventricles measured during postnatal transfrontanellar ultrasound followed by cerebral MRI ,
Time frame: From the time of birth until 12 months of life
Proportion of patients with reversal of hindbrain herniation (i.e. lower limit of the vermis located above the foramen magnum on cerebral MRI)
Time frame: From the time of birth until 12 months of life
Proportion of patients requiring a cerebrospinal fluid shunt within the first 12 months of life
Assistance Publique - Hôpitaux de Paris
Other
Acronym: PRIUM2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04362592
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Los Angeles, California, United States
View Trial DetailsNCT03090633
Arnold-Chiari Malformation, Chiari Malformation Type 2
Baltimore, Maryland, United States
View Trial DetailsNCT06904612
Abnormalities, Severe Teratoid, Anemia
Orlando, Florida, United States
View Trial DetailsNCT06946563
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Portland, Oregon, United States
View Trial Details